{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-066641","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.094916+00:00","generated_at":"2026-05-31T10:48:30.023592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q2 revenue $18.8M (+36% YoY); GAAP EPS loss $(0.22); guides FY rev >=$100M","bullets":["Revenue $18.8M (+36% YoY); gross profit $11.7M (+50%); gross margin 62%.","GAAP net loss $(4.0M) ($(0.22)/share); non-GAAP net income $0.3M ($0.02/diluted).","Adjusted EBITDA $0.5M vs $(0.8M) prior year; FY2024 guidance reaffirmed: rev >=$100M, Adj EBITDA >=$11M.","CEO cites ~$6M DAAP program delayed from Q2; without delay would have exceeded consensus.","KPIs: avg rev per top 20 pharma $2.7M (up from $1.8M); net revenue retention 124% (vs 89%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-066641","json":"https://secwatch.observer/filing/0001213900-24-066641.json","markdown":"https://secwatch.observer/filing/0001213900-24-066641.md","text":"https://secwatch.observer/filing/0001213900-24-066641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/0001213900-24-066641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/ea0210870-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:30.023592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}